<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01031199</url>
  </required_header>
  <id_info>
    <org_study_id>13101</org_study_id>
    <secondary_id>2008-000981-22</secondary_id>
    <nct_id>NCT01031199</nct_id>
  </id_info>
  <brief_title>Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers</brief_title>
  <official_title>Open-label, Non-randomized, Positron Emission Tomography (PET) Imaging Study to Evaluate a Single Dose of 140 MBq (ca. 5 mSv) ZK 6032924 (BAY85-8101) for Its Diagnostic Potential in Either Drug-naïve or Specifically (IFN-beta) Pretreated Patients With Multiple Sclerosis (MS) With Acute Relapse or Patients With Clinically Isolated Syndrome (CIS), Compared to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PET (positron emission tomography) imaging with BAY85-8101 for investigation in patients with
      Multiple Sclerosis compared to healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard quantification variables derived from 3D PET imaging and brain modeling.</measure>
    <time_frame>Day of study tracer administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual analysis/description of the uptake and description of brain PET scans.</measure>
    <time_frame>Day of study tracer administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standard Safety Parameter: Adverse Event Collection</measure>
    <time_frame>maximum time from Screening to Follow-up are 37days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard Safety Parameter: Electrocardiogram</measure>
    <time_frame>maximum time from Screening to Follow-up are 37days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard Safety Parameter: Safety laboratory</measure>
    <time_frame>maximum time from Screening to Follow-up are 37days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard Safety Parameter: Vital signs</measure>
    <time_frame>maximum time from Screening to Follow-up are 37days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Positron-Emission Tomography</condition>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F-18 FEDAA1106 (BAY85-8101)</intervention_name>
    <description>MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer &lt; 5 µg, PET</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F-18 FEDAA1106 (BAY85-8101)</intervention_name>
    <description>Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer &lt; 5 µg, PET</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy volunteers for brain imaging:

          -  males or females, age 20 - 55 years

          -  assessment of the brain MRI as &quot;normal (age-appropriate)&quot;

          -  absence of any sign of CNS disease, no co-medi cation Patients for brain imaging

          -  males or females, age 20 - 55 years

          -  patients with previously diagnosed MS, presenting with acute relapse, without any
             current immunomodulating therapy for MS (&quot;drug-naïve&quot;), or patients presenting with
             first clinical episode suggestive of demyelinating disease (Clinically Isolated
             Syndrome, CIS)

          -  patients with previously diagnosed MS, presenting with acute relapse, receiving
             currently immunomodulatory therapy exclusively with interferon β

          -  MRI: &gt;/= 2 T2 lesions and &gt;/= 1 Gadolinium- (Gd-) enhancing lesion

        Exclusion Criteria:

        Exclusion criteria for all healthy volunteers and patients:

          -  Pregnancy or lactation

          -  Any disease, condition, or concomitant medications that significantly compromises the
             function of the body systems and could result in excessive accumulation, impaired
             metabolism, altered excretion of the radiotracer, or might interfere with the conduct
             of the study or interpretation of the results

          -  other forms of diseases with neuroinflammatory components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2009</study_first_submitted>
  <study_first_submitted_qc>December 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2009</study_first_posted>
  <last_update_submitted>April 1, 2014</last_update_submitted>
  <last_update_submitted_qc>April 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Diagnostic imaging</keyword>
  <keyword>Neuroinflammation</keyword>
  <keyword>PET diagnosis</keyword>
  <keyword>PET tracer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

